Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases

Journal of Thrombosis and Thrombolysis

Volumn 38, Issue 3, 2014, Pages 306-313

  Yusuf, Hussain R ^a   Hooper, W Craig ^a   Beckman, Michele G ^a   Zhang, Qing C ^a   Tsai, James ^a   Ortel, Thomas L ^b  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autoimmune diseases; Autoimmune hemolytic anemia; Immune thrombocytopenic purpura; Rheumatoid arthritis; Systemic lupus erythematosus; Venous thromboembolism

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ADULT; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; VENOUS THROMBOEMBOLISM; AUTOIMMUNE DISEASES; FACTUAL DATABASE; UNITED STATES;

ADULT; AUTOIMMUNE DISEASES; DATABASES, FACTUAL; FEMALE; HOSPITALIZATION; HUMANS; MALE; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84906933702     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1050-0     Document Type: Article

References (31)

1. Raskob GE, Silverstein R, Bratzler DW et al (2010) Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med 38(4):S502-S509. doi:10.1016/j.amepre.2010.01.010
2. Silverstein MD, Heit JA, Mohr DN et al (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25 years population-based study. Arch Intern Med 158:585-593 (Pubitemid 28144815)
3. Heit JA (2005) Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 3:1611-1617
4. Hoffman PC (2009) Immune hemolytic anemia - selected topics. Hematol Am Soc Hematol Educ Program. doi:10.1182/asheducation-2009.1.80
5. Palatinus A, Adams M (2009) Thrombosis in systemic lupus erythematosus. Semin Thromb Hemost 35:621-629. doi:10.1055/s-0029-1242716
6. Matta F, Singala R, Yaekoub AY, Najjar R, Stein PD (2009) Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost 101:134-138
7. Severinsen MT, Engebjerg MC, Farkas DK et al (2011) Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 152(3):360-362. doi:10.1111/j.1365-2141.2010.08418.x
8. Pullarkat V, Ngo M, Iqbal S et al (2002) Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism. Br J Haematol 118(4):1166-1169 (Pubitemid 35025986)
9. Ramagopalan SV, Wotton CJ, Handel AE et al (2011) Risk of venous thromboembolism in people admitted to hospital with selected immune diseases: record linkage study. BMC Med 9:1-8. doi:10.1186/1741-7015-9-1
10. Zoller B, Li X, Sundquist K (2012) Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 21:244-249. doi:10.1016/S0140-6736(11)61306-8
11. Zöller B, Li X, Sundquist J, Sundquist K (2012) Autoimmune diseases and venous thromboembolism: a review of the literature. Am J Cardiovasc Dis 2(3):171-183
12. Cogo A, Bernardi E, Prandoni P et al (1994) Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med 154:164-168 (Pubitemid 24032190)
13. Spencer FA, Emery C, Lessard D et al (2006) The Worcester venous thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Genintern Med 21:722-727 (Pubitemid 43973557)
14. Heit JA, Melton LJ 3rd, Lohse CM et al (2001) Incidence of venous thromboembolism in hospitalized patients versus community residents. Mayo Clin Proc 76(11):1102-1110 (Pubitemid 33032387)
15. Stein PD, Matta F (2010) Epidemiology and incidence: the scope of the problem and risk factors for development of venous thromboembolism. Clin Chest Med 31:611-628. doi:10.1016/j.ccm.2010.07.001
16. Xu J, Lupu F, Esmon CT (2010) Inflammation, innate immunity and blood coagulation. Hamostaseologie 30(1):5-6
17. Sangle NA, Smock KJ (2011) Antiphospholipid antibody syndrome. Arch Pathol Lab Med 135:1092-1096. doi:10.5858/2010-0325-RSR.1
18. de Groot PG, Lutters B, Derksen RH et al (2005) Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 3(9):1993-1997 (Pubitemid 43086056)
19. George D, Erkan D (2009) Antiphospholipid syndrome. Rev Prog Cardiovasc Dis 52(2):115-125. doi:10.1016/j.pcad.2009.06.005
20. Johannesdottir SA, Horváth-Puhó E, Dekkers OM et al (2013) Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 173(9):743-752. doi:10.1001/jamainternmed.2013.122
21. van Zaane B, Nur E, Squizzato A et al (2010) Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. J Thromb Haemost 8(11):2483-2493. doi:10.1111/j.1538-7836.2010.04034.x
22. Calvo-Alén J, Toloza SM, Fernández M et al (2005) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum 52(7):2060-2068 (Pubitemid 40994330)
23. Huerta C, Johansson S, Wallander MA, García Rodríguez LA (2007) Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 167(9):935-943 (Pubitemid 46762756)
24. Van Zaane B, Nur E, Squizzato A et al (2009) Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab 94(8):2743-2750. doi:10.1210/jc.2009-0290
25. Falanga A, Marchetti M (2012) Anticancer treatment and thrombosis. Thromb Res 129(3):353-359. doi:10.1016/j.thromres.2011.10.025
26. Murphy G, Lisnevskaia L, Isenberg D (2013) Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. Lancet 382(9894):809-818. doi:10.1016/S0140-6736(13)60889-2
27. Danese S, Papa A, Saibeni S et al (2007) Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am J Gastroenterol 102:174-186 (Pubitemid 46072059)
28. Johannesdottir SA, Schmidt M, Horváth-Puhó E, Sørensen HT (2012) Autoimmune skin and connective tissue diseases and risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 10(5):815-821. doi:10.1111/j.1538-7836.2012.04666.x
29. Mok CC, Ho LY, Yu KL, To CH (2010) Venous thromboembolism in southern Chinese patients with systemic lupus erythematosus. Clin Rheumatol 29(6):599-604. doi:10.1007/s10067-009-1364-z
30. White RH, Garcia M, Sadeghi B et al (2010) Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. Thromb Res 126:61-67. doi:10.1016/j.thromres.2010.03.009
31. Kahn SR, Lim W, Dunn AS et al (2012) Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2):e195S-e226S